Literature DB >> 21118707

Formation, characterization, and fate of inhaled drug nanoparticles.

Jian Zhang1, Libo Wu, Hak-Kim Chan, Wiwik Watanabe.   

Abstract

Nanoparticles bring many benefits to pulmonary drug delivery applications, especially for systemic delivery and drugs with poor solubility. They have recently been explored in pressurized metered dose inhaler, nebulizer, and dry powder inhaler applications, mostly in polymeric forms. This article presents a review of processes that have been used to generate pure (non polymeric) drug nanoparticles, methods for characterizing the particles/formulations, their in-vitro and in-vivo performances, and the fate of inhaled nanoparticles.
Copyright © 2010 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 21118707     DOI: 10.1016/j.addr.2010.11.002

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  35 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

2.  Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.

Authors:  Qi Tony Zhou; Thomas Gengenbach; John A Denman; Heidi H Yu; Jian Li; Hak Kim Chan
Journal:  AAPS J       Date:  2013-10-16       Impact factor: 4.009

Review 3.  Let's get small (and smaller): Combining zebrafish and nanomedicine to advance neuroregenerative therapeutics.

Authors:  David T White; Meera T Saxena; Jeff S Mumm
Journal:  Adv Drug Deliv Rev       Date:  2019-02-12       Impact factor: 15.470

Review 4.  Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.

Authors:  Sharad Mangal; Wei Gao; Tonglei Li; Qi Tony Zhou
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

5.  Porous mannitol carrier for pulmonary delivery of cyclosporine A nanoparticles.

Authors:  Sharon Shui Yee Leung; Jennifer Wong; Heloisa Victorino Guerra; Kevin Samnick; Robert K Prud'homme; Hak-Kim Chan
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

Review 6.  Imaging the paediatric lung: what does nanotechnology have to offer?

Authors:  K L Ordidge; B A Duffy; J A Wells; T L Kalber; S M Janes; M F Lythgoe
Journal:  Paediatr Respir Rev       Date:  2011-08-04       Impact factor: 2.726

Review 7.  Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.

Authors:  Darren Michael Moss; Marco Siccardi
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

8.  In vitro and in vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization.

Authors:  Yi-Bo Wang; Alan B Watts; Jay I Peters; Sha Liu; Ayesha Batra; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2014-05-14       Impact factor: 3.246

9.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

10.  Regional distribution of aerosol deposition in rat lungs using magnetic resonance imaging.

Authors:  Jessica M Oakes; Miriam Scadeng; Ellen C Breen; G Kim Prisk; Chantal Darquenne
Journal:  Ann Biomed Eng       Date:  2013-01-25       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.